Statements (21)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:clinical_trial
|
| gptkbp:clinicalTrials.gov_Identifier |
NCT02631044
|
| gptkbp:conditionStudied |
relapsed or refractory large B-cell lymphoma
|
| gptkbp:enrollment |
over 250 patients
|
| gptkbp:fullName |
TRANSCEND Non-Hodgkin Lymphoma 001
|
| https://www.w3.org/2000/01/rdf-schema#label |
TRANSCEND NHL 001
|
| gptkbp:intervention |
gene therapy
|
| gptkbp:location |
gptkb:United_States
|
| gptkbp:period |
Phase 1
Phase 2 |
| gptkbp:principalInvestigator |
Jeremy S. Abramson
|
| gptkbp:publishedIn |
gptkb:The_Lancet
|
| gptkbp:result |
safety
overall response rate |
| gptkbp:resultsPublished |
yes
|
| gptkbp:sponsor |
gptkb:Bristol_Myers_Squibb
|
| gptkbp:startDate |
2015
|
| gptkbp:status |
completed
|
| gptkbp:studies |
gptkb:lisocabtagene_maraleucel
|
| gptkbp:bfsParent |
gptkb:lisocabtagene_maraleucel
|
| gptkbp:bfsLayer |
7
|